Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study, a randomised controlled trial. [electronic resource]
Producer: 20150904Description: 519-27 p. digitalISSN:- 1468-3296
- Administration, Inhalation
- Aged
- Albuterol -- analogs & derivatives
- Androstadienes -- therapeutic use
- Australia
- Bronchodilator Agents -- therapeutic use
- Dose-Response Relationship, Drug
- Double-Blind Method
- Drug Administration Schedule
- Drug Therapy, Combination
- Female
- Fluticasone
- Forced Expiratory Volume -- drug effects
- Glycopyrrolate -- therapeutic use
- Health Status
- Humans
- Male
- Middle Aged
- New Zealand
- Pulmonary Disease, Chronic Obstructive -- diagnosis
- Risk Factors
- Salmeterol Xinafoate
- Scopolamine Derivatives -- therapeutic use
- Severity of Illness Index
- Surveys and Questionnaires
- Tiotropium Bromide
- Treatment Outcome
No physical items for this record
Publication Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.